KLI

Comparison of RECIST 1.1 and irecist in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Metadata Downloads
Abstract
Despite wide recognition of iRECIST, evidence regarding the impact of iRECIST over RECIST 1.1 is lacking. We aimed to evaluate the impact of iRECIST on assessing treatment efficacy of immune checkpoint inhibitors (ICIs) over RECIST 1.1. Articles that evaluated the treatment response and outcome based on both RECIST 1.1 and iRECIST were eligible. Data regarding overall response rates (ORR) and disease control rate (DCR) based on RECIST 1.1 and iRECIST, and data required to estimate individual patient data of progression-free survival (PFS) were extracted. Estimates were compared using meta-regression and pooled incidence rate ratios. The pooled difference of restricted mean survival time (RMST) of PFS between two criteria were calculated. Eleven studies with 6210 patients were analyzed. The application of iRECIST had no impact on the response-related endpoint by showing no significantly different ORR and DCR from RECIST 1.1 (pooled ORR, 23.6% and 24.7% [p = 0.72]; pooled DCR, 45.3% and 48.7% [p = 0.56] for iRECIST and RECIST 1.1, respectively) and had a minor impact on a survival endpoint by showing longer RMST of PFS than RECIST 1.1 (pooled difference, 0.46 months; 95% CI, 0.10?0.82 months; p = 0.01). Such a modest benefit of iRECIST should be considered when we design a clinical trial for immune checkpoint inhibitors.
Author(s)
박효정김건하김경원이충욱윤신교채영광Sree Harsha TirumaniNikhil H. Ramaiya
Issued Date
2021
Type
Article
Keyword
RECISTcheckpoint inhibitoriRECISTimmunotherapytreatment efficacy
DOI
10.3390/cancers13010120
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7362
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_doaj_primary_oai_doaj_org_article_3e6c7cc83c994d79bbafdc6e9986de77&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Comparison%20of%20RECIST%201.1%20and%20irecist%20in%20patients%20treated%20with%20immune%20checkpoint%20inhibitors:%20A%20systematic%20review%20and%20meta-analysis&offset=0&pcAvailability=true
Publisher
Cancers
Location
스위스
Language
영어
ISSN
2072-6694
Citation Volume
13
Citation Number
1
Citation Start Page
1
Citation End Page
14
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.